Crinetics Pharmaceuticals, Inc. — Director's Dealing 2018

Jul 18, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2018-07-17

Reporting Person: Fust Matthew K (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12536	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.45	2027-11-05	Common Stock (5700)		Direct
Stock Option (right to buy)	$1.91	2028-03-16	Common Stock (45592)		Direct

Footnotes

F1: The option was initially granted with respect to 6,079 shares. 1/48th of the shares subject to the option vested on January 1, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. The option was partially exercised with respect to 379 shares on March 27, 2018, which shares are included in the total number of shares of common stock owned by the Reporting Person in Table I above.

F2: The option is exercisable as to vested and unvested shares. 1/3rd of the shares subject to the option vest on February 16, 2019, and 1/36th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.